As reported in the EMBO Molecular Medicine journal, researchers have discovered there are several types of dendritic cells within human skin that play a role in both the earlier and more advances stages of psoriasis.
On March 21, 2014, the US Food and Drug Administration announced the approval of Celgene Corporation’s Otezla (apremilast), an oral tablet indicated to treat active psoriatic arthritis in adults. Otezla has a single contraindication: known hypersensitivity to the active ingredient or any excipients in Otezla tablets.
Psoriatic arthritis may be difficult to distinguish from other types of arthritis. According to results of a new study, assessing a patient’s sense of balance and hearing ability may be an aid in the diagnosis.
Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.
Psoriasis, plaguing patients with its seemingly incurable symptoms, may have met its match. Skylit Medical, a startup in San Diego, is developing a phototherapy device to use as treatment for psoriasis as well as eczema and vitiligo.
Ixekizumab, a drug being evaluated for the treatment of moderate-to-severe chronic plaque psoriasis, continues to demonstrate efficacy and safety in Phase III trials.